Sawai Group Holdings Co., Ltd.
【Sawai Group Holdings】Notice of Business Reorganization and Stock Split｜June 2026
Sawai Group Holdings will implement a company split effective September 1, 2026, to transfer the non-alcoholic fatty liver disease treatment app business to a wholly owned subsidiary, Sawai Pharmaceutical Co., Ltd., aiming to improve business efficiency and corporate value.
Key Figures
- Total Assets: Unknown
- Total Liabilities: 100 million yen
- Net Income attributable to owners of parent: 10,438 million yen
AI要約
Overview of Business Reorganization and Company Split
Sawai Group Holdings will implement a company split effective September 1, 2026, to transfer the NASH app business to its wholly owned subsidiary Sawai Pharmaceutical Co., Ltd. This split is a simplified absorption-type split based on Article 784, Paragraph 2 of the Companies Act, with no allotment of shares or providing consideration. Details of assets and liabilities will be announced once finalized, with the aim of streamlining operations and enhancing sustainable corporate value. There will be no change in the company's capital stock, basic management structure, location, or representative as a result of the split.
Future Outlook and Impact
This company split is a business reorganization between the company and its wholly owned subsidiary, and its impact on consolidated performance is expected to be minimal. By promoting the NASH app business and accelerating commercialization, the company aims to enhance its value as a comprehensive healthcare company. Details regarding finalized assets, liabilities, and schedule will be disclosed as they become available.
Sawai Group Holdings Co., Ltd.
Company overview · Stock price · Financial data · All IR
